ESPR up +7.20% percent right now. $ESPR High is at
Post# of 53553
Posted On: 11/11/2014 1:03:23 PM
ESPR up +7.20% percent right now. $ESPR High is at 28.00 and the Low 25.85 with current volume of 67,858.
Recent News posted below.
ESPR Esperion Therapeutics Inc Recent Headline News
Esperion Therapeutics' (ESPR) CEO Tim Mayleben on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 9:25PM CST
ESPR: 27.64 (+1.81)
Esperion Therapeutics beats by $0.04
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 3:27PM CST
ESPR: 27.64 (+1.81)
Esperion Therapeutics Provides ETC-1002 Development Program Update; Reports Third Quarter 2014 Financial Results
Business Wire - Mon Nov 10, 3:05PM CST
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today provided ETC-1002 development program updates and financial results for the third quarter ended September 30, 2014.
ESPR: 27.64 (+1.81)
Esperion Therapeutics to Present at Credit Suisse Healthcare Conference
Business Wire - Wed Nov 05, 3:30PM CST
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced that president and chief executive officer, Tim M. Mayleben, will present at the Credit Suisse Healthcare Conference in Phoenix, AZ on Tuesday, November 11, 2014 at 8:00 a.m. Mountain Time/10:00 a.m. Eastern Time.
ESPR: 27.64 (+1.81)
Esperion Therapeutics to Provide Third Quarter 2014 Results
Business Wire - Mon Nov 03, 3:30PM CST
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced it will host a conference call and webcast to report operational and financial results for the third quarter 2014. The webcast will take place on Monday, November 10, 2014 at 4:30 p.m. Eastern Time.
ESPR: 27.64 (+1.81)
InsiderInsights.com Daily Round Up 10/21/14: AGCO, ESPR, FMI, BKCC
InsiderInsights - at Seeking Alpha - Wed Oct 22, 9:56AM CDT
LDRH: 34.74 (+0.08), BKCC: 8.90 (-0.05), RDEN: 18.60 (+0.23), AGCO: 45.09 (-0.15), MLNK: 3.39 (-0.07), ATRA: 28.05 (+1.63), DHR: 81.17 (-0.12), SHLD: 37.80 (-0.92), GOOG: 549.61 (+2.12), HPQ: 36.75 (-0.15), ATNI: 71.53 (-0.64), PM: 88.00 (-0.42), ESPR: 27.64 (+1.81), FMI: 25.34 (+0.63), LNKD: 228.03 (-1.22), MAT: 30.89 (-0.61), SYK: 88.57 (+0.13), IPGP: 73.09 (-0.35)
Multiple Insiders of Esperion Therapeutics, Inc. (ESPR)-NasdaqGM bought Shares of ESPR
M2 - Wed Oct 22, 7:32AM CDT
Reported by InsiderCow.com at 2014-10-21 12:20:02 ET
ESPR: 27.64 (+1.81)
Esperion Therapeutics Announces Closing of Follow-On Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional Shares of Common Stock
Business Wire - Tue Oct 21, 3:05PM CDT
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced the closing of its follow-on public offering of 4,887,500 shares of common stock, offered at a price to the public of $20.00 per share, which includes the exercise in full by the underwriters of their option to purchase 637,500 additional shares of common stock. This exercise brings the net proceeds in the offering to $91.6 million, after deducting underwriting discounts and commissions and expenses payable by Esperion. Esperion intends to use the net proceeds from the offering, as well as its other existing capital resources, to fund the continued development of ETC-1002 through completion of the anticipated Phase 3 development program, which will include several clinical studies; chemistry, manufacturing and controls (CMC) scale up and supplies development; regulatory compliance and the remainder for working capital and general corporate and administrative expenses.
ESPR: 27.64 (+1.81), JPM: 61.75 (-0.18)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Oct 16, 11:45AM CDT
TTPH: 22.96 (-0.92), DLHC: 2.78 (+0.04), TZOO: 12.52 (-0.03), ESI: 10.11 (+0.02), STRP: 17.70 (-0.66), CALI: 1.19 (-0.08), NFLX: 391.60 (+4.33), ZN: 1.72 (-0.02), ESPR: 27.64 (+1.81), EDUC: 4.25 (+0.03), CDNA: 7.00 (+0.59), AHPI: 1.69 (-0.08), CALA: 9.87 (-0.26), IBIO: 1.16 (-0.07), MPO: 3.06 (-0.15), ESSX: 1.05 (-0.12), MSO: 4.18 (-0.05), MITK: 3.35 (+0.20), CNET: 2.14 (-0.01), EXTR: 3.76 (-0.07)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Oct 16, 8:13AM CDT
SD: 3.78 (+0.09), NETE: 1.52 (+0.03), BX: 31.61 (-0.09), ALU: 3.18 (+0.01), NBG: 2.17 (-0.06), BCLI: 3.36 (-0.16), NFLX: 391.60 (+4.33), PBR: 10.42 (-0.20), ESPR: 27.64 (+1.81), CMRX: 32.76 (+0.94), CHK: 23.35 (+0.45), IBIO: 1.16 (-0.07), ITUB: 13.98 (-0.13), SWN: 34.94 (-0.48), ORAN: 16.01 (+0.50), STO: 22.25 (-0.11), OSUR: 9.25 (+0.08), EXTR: 3.76 (-0.07), BHI: 51.14 (-0.50)
Esperion Therapeutics prices public offering at USD20.00 per share
M2 - Thu Oct 16, 5:08AM CDT
Pharmaceutical company Esperion Therapeutics (NasdaqGM:ESPR) said on Wednesday that it has priced its public offering of 4,250,000 shares of its common stock.
ESPR: 27.64 (+1.81)
Esperion Therapeutics Prices Public Offering of Common Stock
Business Wire - Wed Oct 15, 7:00PM CDT
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced the pricing of an underwritten public offering of 4,250,000 shares of its common stock, offered at a price to the public of $20.00 per share. The gross proceeds from this offering to Esperion are expected to be $85 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Esperion. Esperion has granted the underwriters a 30-day option to purchase up to an additional 637,500 shares of its common stock. The offering is expected to close on or about October 21, 2014, subject to customary closing conditions. Esperion intends to use the net proceeds from the offering, as well as its other existing capital resources, to fund the continued development of ETC-1002 through the anticipated Phase 3 development program, which will include several clinical studies; chemistry, manufacturing and controls (CMC) scale up and supplies development; regulatory compliance and the remainder for working capital and general corporate and administrative expenses.
ESPR: 27.64 (+1.81), JPM: 61.75 (-0.18)
Esperion Therapeutics to issue USD85m common shares in public offering
M2 - Wed Oct 15, 6:31AM CDT
Pharmaceutical company Esperion Therapeutics (NasdaqGM:ESPR) said on Tuesday that it plans to offer USD85m of its common stock in an underwritten public offering.
ESPR: 27.64 (+1.81)
Esperion Therapeutics Announces Proposed Public Offering of Common Stock
Business Wire - Tue Oct 14, 3:05PM CDT
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced that it intends to offer and sell, subject to market and other conditions, $85 million of its common stock in an underwritten public offering. Esperion expects to grant the underwriters a 30-day option to purchase up to $12.8 million of additional shares of its common stock.
ESPR: 27.64 (+1.81), JPM: 61.75 (-0.18)
Esperion Therapeutics Slumps: ESPR Falls 6.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 7:48AM CDT
Esperion Therapeutics has been witnessing a flat trend in its current year earnings estimate and its share price has been falling for past 24 hours
ESPR: 27.64 (+1.81), AMPE: 3.64 (-0.06), CEMP: 14.20 (+0.40), CORT: 3.07 (-0.04)
It's True, Small-Cap Biotech Stocks Are Acting Badly These Days
at The Street - Tue Oct 07, 10:39AM CDT
For the past three months, small-cap biotech stocks are underperforming the broader market.
MNOV: 3.07 (+0.03), ESPR: 27.64 (+1.81), ADHD: 3.66 (-0.01), SNSS: 1.69 (-0.01), AMBI: 15.60 (+0.26)
Should Pfizer Inc. Buy This Surprisingly Competitive Biotech Stock?
Brian Orelli, The Motley Fool - Motley Fool - Tue Oct 07, 7:30AM CDT
Amgen is in a race with Sanofi and Regeneron Pharmaceuticals to bring the first PCSK9 inhibitor to the market, but the companies had better watch out for tiny Esperion Therapeutics coming up from behind with its own cholesterol-lowering...
ESPR: 27.64 (+1.81), PFE: 30.25 (+0.05), MRK: 59.60 (+0.79), AMGN: 163.01 (-0.08), SNY: 46.74 (+0.55), REGN: 396.97 (+11.00)
Esperion Therapeutics (ESPR) in Focus: Stock Jumps 5.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 06, 8:18AM CDT
Esperion Therapeutics, Inc. (ESPR) was a big mover last session, as the company saw its shares rise by over 5% on the day.
LCI: 50.91 (-0.90), ESPR: 27.64 (+1.81), CEMP: 14.20 (+0.40), HPTX: 21.84 (+0.26)
ESPERION THERAPEUTICS
at Investor's Business Daily - Wed Oct 01, 5:43PM CDT
ESPERION THERAPEUTICS (ESPR) said phase-2 study of cholesterol drug candidate ETC-1002 showed it significantly cut bad cholesterol. Shares rose 39%.
ESPR: 27.64 (+1.81)
Why Esperion Therapeutics (ESPR) Stock Is Soaring in After-Hours Trading Today
at The Street - Wed Oct 01, 4:08PM CDT
Shares of Esperion Therapeutics (ESPR) surged in after-hours trading Wednesday after the company announced positive results from its Phase 2b study of ETC-1002, its experimental treatment for hypercholesterolemia.
ESPR: 27.64 (+1.81)
Recent News posted below.
ESPR Esperion Therapeutics Inc Recent Headline News
Esperion Therapeutics' (ESPR) CEO Tim Mayleben on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 9:25PM CST
ESPR: 27.64 (+1.81)
Esperion Therapeutics beats by $0.04
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 3:27PM CST
ESPR: 27.64 (+1.81)
Esperion Therapeutics Provides ETC-1002 Development Program Update; Reports Third Quarter 2014 Financial Results
Business Wire - Mon Nov 10, 3:05PM CST
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today provided ETC-1002 development program updates and financial results for the third quarter ended September 30, 2014.
ESPR: 27.64 (+1.81)
Esperion Therapeutics to Present at Credit Suisse Healthcare Conference
Business Wire - Wed Nov 05, 3:30PM CST
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced that president and chief executive officer, Tim M. Mayleben, will present at the Credit Suisse Healthcare Conference in Phoenix, AZ on Tuesday, November 11, 2014 at 8:00 a.m. Mountain Time/10:00 a.m. Eastern Time.
ESPR: 27.64 (+1.81)
Esperion Therapeutics to Provide Third Quarter 2014 Results
Business Wire - Mon Nov 03, 3:30PM CST
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced it will host a conference call and webcast to report operational and financial results for the third quarter 2014. The webcast will take place on Monday, November 10, 2014 at 4:30 p.m. Eastern Time.
ESPR: 27.64 (+1.81)
InsiderInsights.com Daily Round Up 10/21/14: AGCO, ESPR, FMI, BKCC
InsiderInsights - at Seeking Alpha - Wed Oct 22, 9:56AM CDT
LDRH: 34.74 (+0.08), BKCC: 8.90 (-0.05), RDEN: 18.60 (+0.23), AGCO: 45.09 (-0.15), MLNK: 3.39 (-0.07), ATRA: 28.05 (+1.63), DHR: 81.17 (-0.12), SHLD: 37.80 (-0.92), GOOG: 549.61 (+2.12), HPQ: 36.75 (-0.15), ATNI: 71.53 (-0.64), PM: 88.00 (-0.42), ESPR: 27.64 (+1.81), FMI: 25.34 (+0.63), LNKD: 228.03 (-1.22), MAT: 30.89 (-0.61), SYK: 88.57 (+0.13), IPGP: 73.09 (-0.35)
Multiple Insiders of Esperion Therapeutics, Inc. (ESPR)-NasdaqGM bought Shares of ESPR
M2 - Wed Oct 22, 7:32AM CDT
Reported by InsiderCow.com at 2014-10-21 12:20:02 ET
ESPR: 27.64 (+1.81)
Esperion Therapeutics Announces Closing of Follow-On Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional Shares of Common Stock
Business Wire - Tue Oct 21, 3:05PM CDT
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced the closing of its follow-on public offering of 4,887,500 shares of common stock, offered at a price to the public of $20.00 per share, which includes the exercise in full by the underwriters of their option to purchase 637,500 additional shares of common stock. This exercise brings the net proceeds in the offering to $91.6 million, after deducting underwriting discounts and commissions and expenses payable by Esperion. Esperion intends to use the net proceeds from the offering, as well as its other existing capital resources, to fund the continued development of ETC-1002 through completion of the anticipated Phase 3 development program, which will include several clinical studies; chemistry, manufacturing and controls (CMC) scale up and supplies development; regulatory compliance and the remainder for working capital and general corporate and administrative expenses.
ESPR: 27.64 (+1.81), JPM: 61.75 (-0.18)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Oct 16, 11:45AM CDT
TTPH: 22.96 (-0.92), DLHC: 2.78 (+0.04), TZOO: 12.52 (-0.03), ESI: 10.11 (+0.02), STRP: 17.70 (-0.66), CALI: 1.19 (-0.08), NFLX: 391.60 (+4.33), ZN: 1.72 (-0.02), ESPR: 27.64 (+1.81), EDUC: 4.25 (+0.03), CDNA: 7.00 (+0.59), AHPI: 1.69 (-0.08), CALA: 9.87 (-0.26), IBIO: 1.16 (-0.07), MPO: 3.06 (-0.15), ESSX: 1.05 (-0.12), MSO: 4.18 (-0.05), MITK: 3.35 (+0.20), CNET: 2.14 (-0.01), EXTR: 3.76 (-0.07)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Oct 16, 8:13AM CDT
SD: 3.78 (+0.09), NETE: 1.52 (+0.03), BX: 31.61 (-0.09), ALU: 3.18 (+0.01), NBG: 2.17 (-0.06), BCLI: 3.36 (-0.16), NFLX: 391.60 (+4.33), PBR: 10.42 (-0.20), ESPR: 27.64 (+1.81), CMRX: 32.76 (+0.94), CHK: 23.35 (+0.45), IBIO: 1.16 (-0.07), ITUB: 13.98 (-0.13), SWN: 34.94 (-0.48), ORAN: 16.01 (+0.50), STO: 22.25 (-0.11), OSUR: 9.25 (+0.08), EXTR: 3.76 (-0.07), BHI: 51.14 (-0.50)
Esperion Therapeutics prices public offering at USD20.00 per share
M2 - Thu Oct 16, 5:08AM CDT
Pharmaceutical company Esperion Therapeutics (NasdaqGM:ESPR) said on Wednesday that it has priced its public offering of 4,250,000 shares of its common stock.
ESPR: 27.64 (+1.81)
Esperion Therapeutics Prices Public Offering of Common Stock
Business Wire - Wed Oct 15, 7:00PM CDT
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced the pricing of an underwritten public offering of 4,250,000 shares of its common stock, offered at a price to the public of $20.00 per share. The gross proceeds from this offering to Esperion are expected to be $85 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Esperion. Esperion has granted the underwriters a 30-day option to purchase up to an additional 637,500 shares of its common stock. The offering is expected to close on or about October 21, 2014, subject to customary closing conditions. Esperion intends to use the net proceeds from the offering, as well as its other existing capital resources, to fund the continued development of ETC-1002 through the anticipated Phase 3 development program, which will include several clinical studies; chemistry, manufacturing and controls (CMC) scale up and supplies development; regulatory compliance and the remainder for working capital and general corporate and administrative expenses.
ESPR: 27.64 (+1.81), JPM: 61.75 (-0.18)
Esperion Therapeutics to issue USD85m common shares in public offering
M2 - Wed Oct 15, 6:31AM CDT
Pharmaceutical company Esperion Therapeutics (NasdaqGM:ESPR) said on Tuesday that it plans to offer USD85m of its common stock in an underwritten public offering.
ESPR: 27.64 (+1.81)
Esperion Therapeutics Announces Proposed Public Offering of Common Stock
Business Wire - Tue Oct 14, 3:05PM CDT
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced that it intends to offer and sell, subject to market and other conditions, $85 million of its common stock in an underwritten public offering. Esperion expects to grant the underwriters a 30-day option to purchase up to $12.8 million of additional shares of its common stock.
ESPR: 27.64 (+1.81), JPM: 61.75 (-0.18)
Esperion Therapeutics Slumps: ESPR Falls 6.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 7:48AM CDT
Esperion Therapeutics has been witnessing a flat trend in its current year earnings estimate and its share price has been falling for past 24 hours
ESPR: 27.64 (+1.81), AMPE: 3.64 (-0.06), CEMP: 14.20 (+0.40), CORT: 3.07 (-0.04)
It's True, Small-Cap Biotech Stocks Are Acting Badly These Days
at The Street - Tue Oct 07, 10:39AM CDT
For the past three months, small-cap biotech stocks are underperforming the broader market.
MNOV: 3.07 (+0.03), ESPR: 27.64 (+1.81), ADHD: 3.66 (-0.01), SNSS: 1.69 (-0.01), AMBI: 15.60 (+0.26)
Should Pfizer Inc. Buy This Surprisingly Competitive Biotech Stock?
Brian Orelli, The Motley Fool - Motley Fool - Tue Oct 07, 7:30AM CDT
Amgen is in a race with Sanofi and Regeneron Pharmaceuticals to bring the first PCSK9 inhibitor to the market, but the companies had better watch out for tiny Esperion Therapeutics coming up from behind with its own cholesterol-lowering...
ESPR: 27.64 (+1.81), PFE: 30.25 (+0.05), MRK: 59.60 (+0.79), AMGN: 163.01 (-0.08), SNY: 46.74 (+0.55), REGN: 396.97 (+11.00)
Esperion Therapeutics (ESPR) in Focus: Stock Jumps 5.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 06, 8:18AM CDT
Esperion Therapeutics, Inc. (ESPR) was a big mover last session, as the company saw its shares rise by over 5% on the day.
LCI: 50.91 (-0.90), ESPR: 27.64 (+1.81), CEMP: 14.20 (+0.40), HPTX: 21.84 (+0.26)
ESPERION THERAPEUTICS
at Investor's Business Daily - Wed Oct 01, 5:43PM CDT
ESPERION THERAPEUTICS (ESPR) said phase-2 study of cholesterol drug candidate ETC-1002 showed it significantly cut bad cholesterol. Shares rose 39%.
ESPR: 27.64 (+1.81)
Why Esperion Therapeutics (ESPR) Stock Is Soaring in After-Hours Trading Today
at The Street - Wed Oct 01, 4:08PM CDT
Shares of Esperion Therapeutics (ESPR) surged in after-hours trading Wednesday after the company announced positive results from its Phase 2b study of ETC-1002, its experimental treatment for hypercholesterolemia.
ESPR: 27.64 (+1.81)
(0)
(0)